Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria.
Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR. Martinez-Turrillas R, et al. Among authors: salido e. Mol Ther Methods Clin Dev. 2022 Mar 16;25:137-146. doi: 10.1016/j.omtm.2022.03.006. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35402636 Free PMC article.
Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C. Dutta C, et al. Among authors: salido e. Mol Ther. 2016 Apr;24(4):770-8. doi: 10.1038/mt.2016.4. Epub 2016 Jan 13. Mol Ther. 2016. PMID: 26758691 Free PMC article.
Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
Lai C, Pursell N, Gierut J, Saxena U, Zhou W, Dills M, Diwanji R, Dutta C, Koser M, Nazef N, Storr R, Kim B, Martin-Higueras C, Salido E, Wang W, Abrams M, Dudek H, Brown BD. Lai C, et al. Among authors: salido e. Mol Ther. 2018 Aug 1;26(8):1983-1995. doi: 10.1016/j.ymthe.2018.05.016. Epub 2018 Jun 15. Mol Ther. 2018. PMID: 29914758 Free PMC article.
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
Zabaleta N, Barberia M, Martin-Higueras C, Zapata-Linares N, Betancor I, Rodriguez S, Martinez-Turrillas R, Torella L, Vales A, Olagüe C, Vilas-Zornoza A, Castro-Labrador L, Lara-Astiaso D, Prosper F, Salido E, Gonzalez-Aseguinolaza G, Rodriguez-Madoz JR. Zabaleta N, et al. Among authors: salido e. Nat Commun. 2018 Dec 21;9(1):5454. doi: 10.1038/s41467-018-07827-1. Nat Commun. 2018. PMID: 30575740 Free PMC article.
Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.
Martinez-Turrillas R, Rodriguez-Diaz S, Rodriguez-Marquez P, Martin-Mallo A, Salido E, Beck BB, Prosper F, Rodriguez-Madoz JR. Martinez-Turrillas R, et al. Among authors: salido e. Stem Cell Res. 2019 Dec;41:101626. doi: 10.1016/j.scr.2019.101626. Epub 2019 Oct 18. Stem Cell Res. 2019. PMID: 31715429 Free article.
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias.
Moya-Garzon MD, Gomez-Vidal JA, Alejo-Armijo A, Altarejos J, Rodriguez-Madoz JR, Fernandes MX, Salido E, Salido S, Diaz-Gavilan M. Moya-Garzon MD, et al. Among authors: salido s, salido e. J Pers Med. 2021 Jan 27;11(2):74. doi: 10.3390/jpm11020074. J Pers Med. 2021. PMID: 33513899 Free PMC article. Review.
Molecular therapy of primary hyperoxaluria.
Martin-Higueras C, Torres A, Salido E. Martin-Higueras C, et al. Among authors: salido e. J Inherit Metab Dis. 2017 Jul;40(4):481-489. doi: 10.1007/s10545-017-0045-3. Epub 2017 Apr 19. J Inherit Metab Dis. 2017. PMID: 28425073 Review.
269 results